Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
Tianshu LiuYanru QinJin LiRuihua XuJianming XuShujun YangShukui QinYuxian BaiChangping WuYixiang MaoHaiyan WuYilin GeLin ShenPublished in: Cancer communications (London, England) (2019)
OS and PFS were numerically improved by adding pertuzumab to trastuzumab and chemotherapy as first-line treatment in Chinese HER2-positive gastric cancer/GEJC patients, and this regimen demonstrated an acceptable safety profile. Trial registration ClinicalTrials.gov. NCT01774786. Registered on 24 January 2013, https://clinicaltrials.gov/ct2/show/NCT01774786.
Keyphrases
- epidermal growth factor receptor
- metastatic breast cancer
- study protocol
- end stage renal disease
- clinical trial
- phase iii
- ejection fraction
- newly diagnosed
- locally advanced
- phase ii
- small cell lung cancer
- tyrosine kinase
- peritoneal dialysis
- prognostic factors
- young adults
- radiation therapy
- rectal cancer
- positron emission tomography
- chemotherapy induced
- childhood cancer
- pet ct